Skip to main content

2 Result(s)

within Gavin Harper Remove this filter Infectious Diseases Remove this filter

and

  1. Article

    Open Access

    Two-Drug Regimens Dolutegravir/Lamivudine and Dolutegravir/Rilpivirine Are Effective with Few Discontinuations in US Real-World Settings: Results from the TANDEM Study

    Dolutegravir/lamivudine (DTG/3TC) and dolutegravir/rilpivirine (DTG/RPV) are fixed-dose, complete, single-tablet, two-drug regimens (2DRs) indicated for HIV-1. DTG/3TC is approved for antiretroviral therapy (A...

    Stefan Schneider, Gary Blick, Christina Burke… in Infectious Diseases and Therapy (2024)

    Download PDF (1303 KB) View Article

  2. Article

    Open Access

    Real-World Effectiveness of Dolutegravir/Lamivudine in People With HIV-1 in Test-and-Treat Settings or With High Baseline Viral Loads: TANDEM Study Subgroup Analyses

    Dolutegravir/lamivudine (DTG/3TC) was first approved by the US Food and Drug Administration in 2019 for the treatment of antiretroviral therapy (ART)-naive people with HIV-1 based on results from the pivotal G...

    Paul Benson, Jennifer Kuretski, Cynthia Donovan… in Infectious Diseases and Therapy (2024)

    Download PDF (1241 KB) View Article